title: Topical treatment with anti-oxidants and Au nanoparticles promote healing of diabetic wound through receptor for advance glycation end-products.
abstract: Impairment in diabetic wound healing constitutes an enormous biomedical burden. The receptor for advanced glycation end-products (RAGE) expression in the diabetic cutaneous wound may play a key role. However, the relationship between RAGE expression and topical application of anti-oxidant agents with gold nanoparticles (AuNP) in cutaneous diabetic wounds remains unclear. We tested the 3-5 nm AuNP, epigallocatechin gallate (EGCG), and α-lipoic acid (ALA) could change the RAGE expression and be helpful in diabetic wound. The mixture of AuNP+EGCG+ALA (AuEA) significantly attenuated the AGE-induced RAGE protein expression in fibroblasts (Hs68). Topical EGCG+ALA (EA) and AuEA application accelerated wound healing on diabetic mouse skin and decreased the RAGE expression. Vascular endothelial growth factor but not angiopoietin-1 significantly increased after EA or AuEA treatment for 7 days. Angiopoietin-2 significantly decreased at day 7 in AuEA group. Furthermore, immunoblotting of diabetic wound tissue showed significant decrease of CD68 expression from day 3 to day 7. The results suggest that combination of AuNP, EGCG, and ALA significantly accelerated diabetic cutaneous wound healing through angiogenesis regulation and anti-inflammatory effects. Blockade of RAGE by anti-oxidant agents and nanoparticles may restore effective wound healing in diabetic ulcer.
authors.affiliation: Department and Institute of Life Science, Fu-Jen Catholic University, Taipei, Taiwan.
authors.forename: Siang-An
authors.initials: SA
authors.lastname: Chen
authors.forename: Han-Min
authors.initials: HM
authors.lastname: Chen
authors.forename: Yeong-Der
authors.initials: YD
authors.lastname: Yao
authors.forename: Chi-Feng
authors.initials: CF
authors.lastname: Hung
authors.forename: Chi-Shun
authors.initials: CS
authors.lastname: Tu
authors.forename: Yao-Jen
authors.initials: YJ
authors.lastname: Liang
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage*; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002460:Cell Line; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000008:administration & dosage; D006046:Gold / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D053768:Metal Nanoparticles / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism*; D008063:Thioctic Acid / Q000008:administration & dosage; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000975:Antioxidants; D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D008063:Thioctic Acid; D006046:Gold; D002392:Catechin; C045651:epigallocatechin gallate